Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALUR Allurion Technologies	$2.37 -2.1%	$2.57	$2.15 ▼ $64.75	$18.05M	-0.47	779,253 shs	49,944 shs
INO Inovio Pharmaceuticals	$1.96 +0.5%	$1.96	$1.42 ▼ $12.33	$71.51M	1.34	628,304 shs	773,501 shs
NSPR InspireMD	$2.46 +1.7%	$2.49	$2.07 ▼ $3.80	$75.36M	0.59	39,629 shs	43,010 shs
TELA TELA Bio	$1.65 -1.2%	$1.29	$0.86 ▼ $5.56	$66.06M	0.78	231,087 shs	46,242 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALUR Allurion Technologies	-2.87%	-4.82%	-16.43%	-34.09%	-91.06%
INO Inovio Pharmaceuticals	+0.51%	-2.00%	-1.01%	+2.08%	-77.10%
NSPR InspireMD	+1.65%	+6.03%	+10.81%	-10.22%	-10.22%
TELA TELA Bio	-1.20%	-2.94%	+18.71%	+12.24%	-67.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALUR Allurion Technologies	2.8827 of 5 stars	3.5	4.0	0.0	0.5	3.3	0.6
INO Inovio Pharmaceuticals	3.6561 of 5 stars	3.3	2.0	4.3	2.8	0.0	0.6
NSPR InspireMD	2.5518 of 5 stars	3.5	2.0	0.0	2.1	2.5	0.6
TELA TELA Bio	2.1437 of 5 stars	3.4	3.0	0.0	1.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALUR Allurion Technologies	3.00	Buy	$22.83	863.43% Upside
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	397.45% Upside
NSPR InspireMD	3.00	Buy	$4.50	82.93% Upside
TELA TELA Bio	2.75	Moderate Buy	$7.25	339.39% Upside

Current Analyst Ratings Breakdown

Latest ALUR, INO, TELA, and NSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
5/12/2025	NSPR InspireMD	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$4.50 ➝ $4.00
3/27/2025	ALUR Allurion Technologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.50 ➝ $2.50
3/21/2025	ALUR Allurion Technologies	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/21/2025	ALUR Allurion Technologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.50
3/21/2025	TELA TELA Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $7.00
3/21/2025	TELA TELA Bio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$5.00 ➝ $2.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALUR Allurion Technologies	$32.11M	0.55	N/A	N/A	($30.08) per share	-0.08
INO Inovio Pharmaceuticals	$220K	326.70	N/A	N/A	$1.90 per share	1.03
NSPR InspireMD	$7.03M	10.72	N/A	N/A	$1.83 per share	1.34
TELA TELA Bio	$69.30M	0.94	N/A	N/A	$0.72 per share	2.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALUR Allurion Technologies	-$26.15M	-$12.50	N/A	N/A	N/A	-86.05%	N/A	-41.49%	8/12/2025 (Estimated)
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)
NSPR InspireMD	-$19.92M	-$0.79	N/A	N/A	N/A	-413.96%	-69.42%	-57.68%	N/A
TELA TELA Bio	-$37.84M	-$1.41	N/A	N/A	N/A	-61.00%	-402.45%	-62.73%	8/11/2025 (Estimated)

Latest ALUR, INO, TELA, and NSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ALUR Allurion Technologies	-$1.53	$0.43	+$1.96	$0.20	$5.50 million	$5.58 million
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
5/8/2025	Q1 2025	TELA TELA Bio	-$0.21	-$0.25	-$0.04	-$0.25	$17.35 million	$18.52 million
3/26/2025	Q4 2024	ALUR Allurion Technologies	-$5.00	-$7.00	-$2.00	-$7.95	$5.60 million	$5.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALUR Allurion Technologies	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NSPR InspireMD	N/A	N/A	N/A	N/A	N/A
TELA TELA Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALUR Allurion Technologies	N/A	2.09	1.88
INO Inovio Pharmaceuticals	N/A	2.63	2.63
NSPR InspireMD	N/A	6.39	6.05
TELA TELA Bio	2.28	4.22	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALUR Allurion Technologies	21.39%
INO Inovio Pharmaceuticals	26.79%
NSPR InspireMD	44.78%
TELA TELA Bio	94.35%

Insider Ownership

Company	Insider Ownership
ALUR Allurion Technologies	22.40%
INO Inovio Pharmaceuticals	2.30%
NSPR InspireMD	34.06%
TELA TELA Bio	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALUR Allurion Technologies	501	7.46 million	5.79 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
NSPR InspireMD	50	30.64 million	18.33 million	Optionable
TELA TELA Bio	120	39.56 million	37.70 million	Optionable

ALUR, INO, TELA, and NSPR Headlines

Recent News About These Companies

TELA Bio (NASDAQ:TELA) Cut to Sell at Wall Street Zen

June 14, 2025 | americanbankingnews.com

Wall Street Zen Downgrades TELA Bio (NASDAQ:TELA) to Sell

June 14, 2025 | marketbeat.com

TELA Bio Welcomes Jim Hagen with Strategic Equity Grant

June 9, 2025 | msn.com

TELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 7, 2025 | finanznachrichten.de

TELA Bio (NASDAQ:TELA) Stock Rating Upgraded by Wall Street Zen

June 7, 2025 | marketbeat.com

TELA Bio, Inc. Grants Inducement Equity Awards to New Senior Vice President Jim Hagen

June 6, 2025 | quiverquant.com

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

June 5, 2025 | tmcnet.com

TELA Bio, Inc. (NASDAQ:TELA) Short Interest Down 13.6% in May

June 4, 2025 | marketbeat.com

TELA Bio Announces European Commercial Launch of OviTexÂ® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

June 3, 2025 | globenewswire.com

TELA Bio Names Jeffrey Blizard as President to Drive Strategic Growth

June 3, 2025 | msn.com

TELA Bio Appoints Jeffrey Blizard as President to Drive Growth and Innovation

June 2, 2025 | quiverquant.com

TELA Bio Appoints Jeffrey Blizard as President

June 2, 2025 | globenewswire.com

TELA Bio to Present at the 2025 Jefferies Global Healthcare Conference

May 25, 2025 | msn.com

TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 22, 2025 | globenewswire.com

Piper Sandler Sticks to Their Hold Rating for TELA Bio (TELA)

May 22, 2025 | theglobeandmail.com

TELA Bio Announces Inducement Grants to New Hires with 4-Year Vesting Plan

May 12, 2025 | msn.com

TELA Bio Reports Q1 2025 Growth and Product Expansion

May 12, 2025 | msn.com

TELA Bio, Inc. (TELA) Q1 2025 Earnings Call Transcript

May 11, 2025 | seekingalpha.com

Earnings call transcript: Tela Bio Q1 2025 revenue miss, stock rises 9%

May 10, 2025 | uk.investing.com

TELA Bio Reports First Quarter 2025 Financial Results

May 10, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALUR, INO, TELA, and NSPR Company Descriptions

Allurion Technologies NYSE:ALUR

$2.37 -0.05 (-2.07%)

Closing price 06/20/2025 03:58 PM Eastern

Extended Trading

$2.36 -0.01 (-0.42%)

As of 06/20/2025 08:00 PM Eastern

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

Inovio Pharmaceuticals NASDAQ:INO

$1.96 +0.01 (+0.51%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.96 0.00 (-0.26%)

As of 06/20/2025 07:49 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

InspireMD NYSE:NSPR

$2.46 +0.04 (+1.65%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$2.44 -0.02 (-0.81%)

As of 06/20/2025 04:04 PM Eastern

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

TELA Bio NASDAQ:TELA

$1.65 -0.02 (-1.20%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.64 -0.01 (-0.61%)

As of 06/20/2025 04:04 PM Eastern

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time